Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 07 Jun 2017 Biomarkers information updated
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.